Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 35Lymphoma, Large B-Cell, Diffuse 23Lymphoma, Non-Hodgkin 18Hodgkin Disease 13Lymphoma, Mantle-Cell 10Lymphoma, Follicular 10Burkitt Lymphoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Leukemia 8Leukemia, Lymphocytic, Chronic, B-Cell 7Neutropenia 6Lymphoma, B-Cell, Marginal Zone 5Neoplasms 4Multiple Myeloma 4Lymphoma, Large-Cell, Immunoblastic 4Waldenstrom Macroglobulinemia 3Lymphoma, T-Cell, Peripheral 3Lymphoma, B-Cell 3Dendritic Cell Sarcoma, Interdigitating 3Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Prolymphocytic 2Intraocular Lymphoma 2Thrombocytopenia 1Ovarian Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, AIDS-Related 1

Interventions

midostaurin 2selinexor 1pegfilgrastim 1glofitamab 1Topotecan 1Rituximab 1Prednisone 1Positron Emission Tomography Computed Tomography 1Paclitaxel 1Methylprednisolone 1Immunologic Techniques 1Ifosfamide 1Flow Cytometry 1Etoposide 1Dexamethasone 1Clofarabine 1Carboplatin 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Aggression × pegfilgrastim × Lymphoid × Clear all
NCT00038545 2018-10-30

A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
25 enrolled
Lymphoid

Aggression, Lymphoma, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡